We are live on ! Find out more
RIGL icon

Rigel Pharmaceuticals
RIGL

121 hedge funds and large institutions have $316M invested in Rigel Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 43 increasing their positions, 42 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

186% more call options, than puts

Call options by funds: $3.05M | Put options by funds: $1.07M

69% more capital invested

Capital invested by funds: $187M → $316M (+$129M)

6% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 18

2% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 42

1% more funds holding

Funds holding: 120 → 121 (+1)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
121
Holders Change
+1
Holders Change %
+0.83%
% of All Funds
3.23%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
19
Increased
43
Reduced
42
Closed
18
Calls
$3.05M
Puts
$1.07M
Net Calls
+$1.99M
Net Calls Change
+$1.7M

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$6.86M
2
Goldman Sachs
Goldman Sachs
New York
+$4.75M
3
CAM
Cormorant Asset Management
Massachusetts
+$3.31M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$2.19M
5
CS
Candriam SCA
Luxembourg
+$2.08M

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$5.2M
2
DCM
DAFNA Capital Management
California
-$4.32M
3
ACP
Acuta Capital Partners
California
-$2.14M
4
NI
Numeric Investors
Massachusetts
-$1.89M
5
SAM
Senzar Asset Management
New York
-$1.54M
Name Holding Trade Value Shares
Change 		Change in
Stake
PC
26
Paulson & Co
New York
$2.95M -$558K -19,470 -19%
Geode Capital Management
27
Geode Capital Management
Massachusetts
$2.95M +$157K +5,491 +7%
CS
28
Candriam SCA
Luxembourg
$2.66M +$2.08M +72,500 New
GTC
29
Ghost Tree Capital
New York
$2.57M -$287K -10,000 -13%
EI
30
EAM Investors
California
$2.55M +$1.99M +69,504 New
Jacobs Levy Equity Management
31
Jacobs Levy Equity Management
New Jersey
$2.35M -$53.9K -1,880 -3%
Renaissance Technologies
32
Renaissance Technologies
New York
$2.31M -$467K -16,280 -21%
LOAMU
33
Lombard Odier Asset Management (USA)
New York
$1.73M +$1.35M +47,000 New
Bank of New York Mellon
34
Bank of New York Mellon
New York
$1.57M -$22K -766 -2%
EA
35
Emerald Acquisition
Washington
$1.55M +$483K +16,843 +66%
BA
36
BlackRock Advisors
Delaware
$1.41M -$120K -4,172 -10%
BIM
37
BlackRock Investment Management
Delaware
$1.38M +$81.1K +2,830 +8%
Balyasny Asset Management
38
Balyasny Asset Management
Illinois
$1.38M +$1.02M +35,570 +1,843%
JGC
39
J. Goldman & Co
New York
$1.32M -$1.06M -36,817 -50%
NSEDCP
40
NJ State Employees Deferred Compensation Plan
New Jersey
$1.3M +$287K +10,000 +39%
DCM
41
DAFNA Capital Management
California
$1.25M -$4.32M -150,709 -82%
NFA
42
Nationwide Fund Advisors
Ohio
$1.23M +$133K +4,630 +16%
AG
43
Algert Global
California
$1.23M +$247K +8,632 +35%
Connor, Clark & Lunn Investment Management (CC&L)
44
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$1.18M -$313K -10,920 -25%
HT
45
HAP Trading
New York
$1.13M +$882K +30,757 New
Two Sigma Advisers
46
Two Sigma Advisers
New York
$1M +$89.4K +3,120 +13%
Deutsche Bank
47
Deutsche Bank
Germany
$953K +$560K +19,546 +303%
Marshall Wace
48
Marshall Wace
United Kingdom
$765K +$598K +20,851 New
CS
49
Credit Suisse
Switzerland
$748K +$270K +9,410 +86%
Charles Schwab
50
Charles Schwab
California
$740K – – –
1
2
3 4 5

RIGL Hedge Fund Activity: Q3 2016 in Review

121 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q3 2016, worth a combined $316M — up 69% from $187M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new RIGL positions and 18 closed out — a net gain of 1 holder — while 43 added to existing stakes and 42 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $6.86M. The largest seller was Deerfield Management, exiting entirely with an estimated $5.2M sold.

  • 121 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q3 2016, up from 120 in Q2 2016.
  • Funds reported $316M of Rigel Pharmaceuticals stock for Q3 2016, up 69% quarter-over-quarter.
  • 19 funds opened new Rigel Pharmaceuticals positions in Q3 2016 and 18 closed out, a net change of +1 holder.
  • The largest Rigel Pharmaceuticals buyer in Q3 2016 was Citadel Advisors, an estimated $6.86M added.
  • The largest Rigel Pharmaceuticals seller in Q3 2016 was Deerfield Management, an estimated $5.2M sold.

Based on aggregated 13F filings for Q3 2016.